Table 3.
Thresholds | n (%) | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) | Accuracy, % (95% CI) | AUC (95% CI) |
---|---|---|---|---|---|---|---|
All study participants, n = 1115 | |||||||
≥ 6 | 661 (59) | 98 (95–99) | 53 (50–56) | 40 (36–44) | 99 (97–100) | 64 (61–67) | 0.93 (0.91–0.94) |
≥ 7 | 554 (50) | 96 (92–98) | 65 (62–68) | 46 (42–51) | 98 (96–99) | 72 (70–75) | |
≥ 8 | 456 (41) | 94 (90–96) | 76 (73–79) | 55 (51–60) | 97 (96–98) | 80 (78–82) | |
≥ 9 | 373 (33) | 87 (82–90) | 84 (81–86) | 63 (57–67) | 95 (93–97) | 84 (82–86) | |
≥ 10 | 301 (27) | 79 (73–83) | 90 (87–91) | 70 (65–76) | 93 (91–95) | 87 (85–89) | |
With Metabolic syndrome only (WHO definition), n = 384 | |||||||
≥ 6 | 242 (63) | 98 (93–100) | 52 (46–58) | 47 (41–54) | 99 (95–100) | 66 (61–71) | 0.95 (0.92–0.97) |
≥ 7 | 205 (53) | 97 (92–100) | 66 (60–71) | 55 (48–62) | 98 (95–100) | 75 (71–79) | |
≥ 8 | 171 (45) | 95 (89–98) | 77 (72–82) | 64 (57–71) | 97 (94–99) | 83 (78–86) | |
≥ 9 | 146 (38) | 91 (83–95) | 85 (80–89) | 72 (64–79) | 95 (92–98) | 86 (83–90) | |
≥ 10 | 119 (31) | 84 (75–90) | 92 (88–95) | 82 (73–88) | 93 (89–96) | 89 (86–92) | |
Without Metabolic syndrome only (WHO definition), n = 731 | |||||||
≥ 6 | 419 (57) | 98 (94–100) | 53 (49–58) | 36 (31–41) | 99 (97–100) | 63 (59–66) | 0.91 (0.89–0.94) |
≥ 7 | 349 (48) | 94 (89–97) | 65 (60–68) | 41 (36–47) | 98 (95–99) | 71 (67–74) | |
≥ 8 | 285 (39) | 93 (87–96) | 75 (72–79) | 50 (44–56) | 98 (95–99) | 79 (76–82) | |
≥ 9 | 227 (31) | 84 (77–89) | 83 (80–86) | 56 (50–63) | 95 (93–97) | 83 (80–86) | |
≥ 10 | 182 (25) | 75 (67–82) | 88 (85–91) | 63 (56–70) | 93 (91–95) | 86 (83–88) |
PPV positive predictive value, NPV negative predictive value, AUC area under the receiver operating curve, CI confidence interval
Optimal thresholds in bold